文献速递脊柱关节炎

强直性脊柱炎与癌症风险的关联:队列研究的荟萃分析

Association of ankylosing spondylitis with the risk of cancer: a meta-analysis of cohort studies.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该荟萃分析纳入20项队列、超过33万名参与者,探讨强直性脊柱炎(AS)与各类癌症风险的关系。汇总分析显示AS与癌症风险升高相关(RR=1.16,95%CI:1.07-1.26,P=0.001,I²=70.60%),亚洲人群风险升高而欧洲人群关联不显著,骨癌、甲状腺癌、多发性骨髓瘤、白血病、肾癌、前列腺癌和非霍奇金淋巴瘤风险升高,但与结缔组织癌、脑癌、睾丸及其他男性癌、膀胱癌、女性癌、皮肤癌及消化系统和呼吸系统癌症无显著相关。

要点

  • AS与总体癌症风险升高相关(RR=1.16,95%CI:1.07-1.26,P=0.001,I²=70.60%)。
  • 亚洲人群AS癌症风险升高,欧洲人群该关联不显著。
  • 骨癌(RR=3.41)、甲状腺癌(RR=1.76)、多发性骨髓瘤(RR=1.74)等风险升高。

核心结论

  • AS似乎与癌症发生相关,但需要大规模研究并考虑AS病程、用药史和潜在偏倚等因素。

研究设计与样本

  • 检索PubMed、EMBASE和Cochrane Library截至2023年7月10日的文献,由两名研究者筛选合格研究并提取数据。
  • 采用随机效应模型分析AS与癌症的关联,效应量为相对风险(RR)。
  • 共纳入20项队列,参与者超过33万人。

主要发现

  • 汇总分析显示AS与癌症风险升高相关(RR=1.16,95%CI:1.07-1.26,P=0.001,I²=70.60%)。
  • 亚组分析显示AS在亚洲人群癌症风险较高,但在欧洲该关联不显著。
  • AS与骨癌风险升高相关(RR=3.41,95%CI:1.45-7.99,P=0.005,I²=0.00%)。
  • AS与甲状腺癌(RR=1.76,95%CI:1.29-2.40,P<0.001,I²=13.70%)、多发性骨髓瘤(RR=1.74,95%CI:1.42-2.15,P<0.001,I²=27.20%)、白血病(RR=1.52,95%CI:1.27-1.82,P<0.001,I²=0.00%)、肾癌(RR=1.45,95%CI:1.08-1.94,P=0.014,I²=0.00%)、前列腺癌(RR=1.43,95%CI:1.17-1.74,P<0.001,I²=82.80%)和非霍奇金淋巴瘤(RR=1.42,95%CI:1.17-1.73,P<0.001,I²=0.00%)风险升高相关。
  • AS与结缔组织癌、脑癌、睾丸及其他男性癌、膀胱癌、女性癌、皮肤癌及消化系统和呼吸系统癌症无显著相关。

关键数值与推荐

  • AS与总体癌症风险的RR=1.16(95%CI:1.07-1.26,P=0.001,I²=70.60%)。
  • 骨癌RR=3.41(95%CI:1.45-7.99,P=0.005,I²=0.00%)。
  • 甲状腺癌RR=1.76(95%CI:1.29-2.40,P<0.001,I²=13.70%)。
  • 多发性骨髓瘤RR=1.74(95%CI:1.42-2.15,P<0.001,I²=27.20%)。
  • 白血病RR=1.52(95%CI:1.27-1.82,P<0.001,I²=0.00%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 汇总分析异质性I²=70.60%。
  • 前列腺癌分析异质性I²=82.80%。
  • 作者指出需要大规模研究,并考虑AS病程、用药史和潜在偏倚等因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The potential impact of ankylosing spondylitis (AS) on cancer risk remains unclear. This study seeks to investigate the relationship between AS and different types of cancers. METHODS: A literature search on PubMed, EMBASE and Cochrane Library up to 10 July 2023 was conducted. Two investigators selected eligible studies and extracted relevant data. The study used the random-effects model to explore the causality between AS and cancer, utilizing relative risk (RR) as a measure for the study. RESULTS: A total of 20 cohorts with >330 000 participants were included. The pooling analysis shows AS being associated with a higher risk of cancers (RR = 1.16, 95% CI: 1.07-1.26, P = 0.001, I2 = 70.60%). In the subgroup analysis, AS has a higher cancer risk in Asia, but this association is not significant in Europe. Individual investigations indicate that AS is associated with an increased risk of bone cancer (RR = 3.41, 95% CI: 1.45-7.99, P = 0.005, I2 = 0.00%), thyroid gland cancer (RR = 1.76, 95% CI: 1.29-2.40, P < 0.001, I2 = 13.70%), multiple myeloma (RR = 1.74, 95% CI: 1.42-2.15, P < 0.001, I2 = 27.20%), leukaemia (RR = 1.52, 95% CI: 1.27-1.82, P < 0.001, I2 = 0.00%), kidney cancer (RR = 1.45, 95% CI: 1.08-1.94, P = 0.014, I2 = 0.00%), prostate cancer (RR = 1.43, 95% CI: 1.17-1.74, P < 0.001, I2 = 82.80%) and non-Hodgkin's lymphoma (RR = 1.42, 95% CI: 1.17-1.73, P < 0.001, I2 = 0.00%). However, there is no significant correlation with connective tissue cancer, brain cancer, testicular and other male cancers, bladder cancer, female cancers, skin cancer, and cancers of the digestive system and respiratory system. CONCLUSION: AS appears to be related to cancer development. The results highlighted the necessity for large-scale studies, considering influencing factors such as AS course, medication histories and potential biases when examining cancer risk.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Yu L, Yan Y, Liu W, et al. Association of ankylosing spondylitis with the risk of cancer: a meta-analysis of cohort studies. Rheumatology (Oxford). 2025. PMID: 38830028. doi:10.1093/rheumatology/keae294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。